Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Pharmacokinetics and Drug–Drug Interactions of Elbasvir/Grazoprevir
Tony K. L. Kiang
European Journal of Drug Metabolism and Pharmacokinetics (2018) Vol. 43, Iss. 5, pp. 509-531
Closed Access | Times Cited: 9

Showing 9 citing articles:

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice
Nicola Ferri, E. Colombo, Marco Tenconi, et al.
Pharmaceutics (2022) Vol. 14, Iss. 6, pp. 1120-1120
Open Access | Times Cited: 78
Direct‐acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients
Kuntheavy Ing Lorenzini, François Girardin
Liver International (2019) Vol. 40, Iss. 1, pp. 32-44
Open Access | Times Cited: 22
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel
William L. Marshall, Hwa-ping Feng, Luzelena Caro, et al.
European Journal of Clinical Pharmacology (2017) Vol. 73, Iss. 5, pp. 593-600
Closed Access | Times Cited: 10
Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities
Sibasish Manna, Koushik K. Das, Sougata Santra, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1826-1826
Open Access | Times Cited: 2
Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents
Michael T. Murray
Clinical Pharmacokinetics (2023) Vol. 62, Iss. 10, pp. 1365-1392
Closed Access | Times Cited: 2
Interactions of Drugs for Liver Diseases
Marina Mudrovčić, Lucija Jukić, Doris Ogresta, et al.
Clinical gastroenterology (2024), pp. 575-639
Closed Access
Antiviral (Hepatitis C Virus) Drug-Drug Interaction Leading to Dramatic Underestimation of Liver Function With 99mTc-Mebrofenin Hepatobiliary Scintigraphy
Emmanuel Deshayes, Cyril Fersing, Lucy Meunier, et al.
Clinical Nuclear Medicine (2019) Vol. 45, Iss. 2, pp. 133-135
Closed Access | Times Cited: 2
General Framework to Quantitatively Predict Pharmacokinetic Induction Drug–Drug Interactions Using In Vitro Data
Sandra Grañana‐Castillo, Angharad Williams, Thao Pham, et al.
Clinical Pharmacokinetics (2023) Vol. 62, Iss. 5, pp. 737-748
Closed Access
Drug Combination Strategy: Pharmacokinetics and Drug-Drug Interaction Considerations in Diseased Patients
Nuggehally R. Srinivas
Journal of Bioequivalence & Bioavailability (2018) Vol. 10, Iss. 3
Open Access
Page 1

Scroll to top